BioMarin Pharmaceutical

from Wikipedia, the free encyclopedia
BioMarin Pharmaceutical Inc.

logo
legal form Corporation
ISIN US09061G1013
founding 1997
Seat San Rafael , United StatesUnited StatesUnited States 
management Jean-Jacques Bienaimé (CEO)
Number of employees 2,581 (2017)
sales 1,491,000,000 US dollars (2018)
Branch Pharma
Website www.biomarin.com

BioMarin Pharmaceutical is an American biotechnology company headquartered in San Rafael , California . It has offices and facilities in the United States, South America, Asia, and Europe. The company specializes in life-threatening and rare genetic diseases. The core business and main research area of ​​BioMarin are enzyme replacement therapies . BioMarin was the first to offer therapeutics for mucopolysaccharidosis type I (MPS I) through the manufacture of iduronidase (Aldurazyme, sold by Genzyme Corporation). BioMarin was also the first to offer therapeutics for phenylketonuria (PKU).

The company has been part of the NASDAQ-100 stock exchange index since 2015 .

history

The company was founded in 1997 by Christopher Starr and Grant W. Denison Jr. with a $ 1.5 million investment from Glyko Biomedical . Private investors raised more than $ 11 million in capital that same year. The company has been listed on the stock exchange since 1999. A clinical study started in 1997 for Aldurazyme, its first drug for the indication of mucopolysaccharidosis type I. Since 2003 BioMarin has been allowed to sell this drug commercially in Europe and North America.

BioMarin Pharmaceutical took over several smaller companies over time, including the Dutch biotechnology company Prosensa in 2014 , which was acquired for a sum of 840 million US dollars.

In 2019, several media reported that BioMarin had refused to release the drug sapropterin (Kuvan), which had been successfully tested several times , in order to benefit financially. Several people were harmed as a result. A test patient therefore had to live permanently disabled again due to phenylketonuria .

Web links

Individual evidence

  1. ^ History. In: BioMarin. Retrieved November 29, 2019 (American English).
  2. ↑ Overview of BioMarin: History and Product Portfolio. In: Market Realist. January 11, 2016. Retrieved November 29, 2019 (American English).
  3. ↑ BioMarin to Acquire Prosensa for Up to $ 840M. In: GEN - Genetic Engineering and Biotechnology News. November 24, 2014. Retrieved November 29, 2019 (American English).
  4. ↑ 'I helped test a wonder drug - then I was denied it' . April 17, 2019 ( bbc.com [accessed November 29, 2019]).